AWM
SLRN

Avior Wealth Management’s ACELYRIN SLRN Stock Holding History

Avior Wealth Management’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7
Closed -$47 – 3507
2024
Q1 		$47 Buy
+7
New +$53 ﹤0.01% 3489

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Avior Wealth Management's SLRN Position: Q2 2024 in Review

Avior Wealth Management sold out of ACELYRIN (SLRN) in Q2 2024, closing a stake of 7 shares — an estimated $47 sold.

Avior Wealth Management first reported a position in SLRN in Q1 2024 and held it in 1 quarter. The position peaked at $47 in Q1 2024. 112 funds tracked by Wall St. Rank hold SLRN as of Q2 2024.

  • Avior Wealth Management reported no remaining ACELYRIN position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 7 ACELYRIN shares in Q2 2024, an estimated $47.
  • Avior Wealth Management first reported a position in ACELYRIN in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's ACELYRIN position peaked at $47 in Q1 2024.
  • 112 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.